Intercept's lead drug boasts success in PhIII after worrisome side-effects disclosure

Intercept Pharmaceuticals ($ICPT) delivered a bad news-good news punch over the weekend. Friday night, the company disclosed some serious heart-related adverse events in a study of its lead drug OCA (obeticholic acid). Sunday morning, the company offered an upbeat counterpoint, with some positive Phase III data on the drug. Report